Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab US Large-Cap Growth ETF
SCHG
|
+$2.6B |
| 2 |
Abbott
ABT
|
+$1.29B |
| 3 |
Home Depot
HD
|
+$1.03B |
| 4 |
Devon Energy
DVN
|
+$888M |
| 5 |
PepsiCo
PEP
|
+$880M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$1.6B |
| 2 |
Schwab Fundamental US Small Company Index ETF
FNDA
|
+$1.5B |
| 3 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$1.34B |
| 4 |
Texas Instruments
TXN
|
+$1.32B |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$789M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.11% |
| 2 | Financials | 10.61% |
| 3 | Healthcare | 10.33% |
| 4 | Miscellaneous | 9.93% |
| 5 | Industrials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
Harmony Biosciences
HRMY
$2.42B
| $15.4M | ﹤0.01% |
423,824
+12,227
| +3% | +$386K |
|
1952
Bristow Group
VTOL
$1.28B
| $15.4M | ﹤0.01% |
373,394
-8,904
| -2% | -$399K |
|
1953
CONMED
CNMD
$1.41B
| $15.4M | ﹤0.01% |
471,022
-7,581
| -2% | -$273K |
|
1954
Beazer Homes USA
BZH
$887M
| $15.3M | ﹤0.01% |
547,058
-107,788
| -16% | -$2.55M |
|
1955
CareDx
CDNA
$2.59B
| $15.3M | ﹤0.01% |
538,125
+27,720
| +5% | +$603K |
|
1956
Stoke Therapeutics
STOK
$1.93B
| $15.3M | ﹤0.01% |
467,012
+29,837
| +7% | +$958K |
|
|
FRVO
1957
Fervo Energy
FRVO
$5.08B
| $15.3M | ﹤0.01% |
+522,706
| New | +$18.9M |
|
1958
Arlo Technologies
ARLO
$1.41B
| $15.2M | ﹤0.01% |
1,130,982
+98,362
| +10% | +$1.33M |
|
1959
Kelly Services Class A
KELYA
$554M
| $15.2M | ﹤0.01% |
1,240,890
-452,802
| -27% | -$4.71M |
|
1960
Seneca Foods Class A
SENEA
$1.3B
| $15.2M | ﹤0.01% |
87,317
-14,220
| -14% | -$2.11M |
|
1961
Recursion Pharmaceuticals
RXRX
$1.72B
| $15.2M | ﹤0.01% |
4,138,286
+329,488
| +9% | +$1.1M |
|
1962
KE Holdings
BEKE
$18.6B
| $15.1M | ﹤0.01% |
1,037,308
+23,985
| +2% | +$395K |
|
1963
Ocular Therapeutix
OCUL
$2.52B
| $15.1M | ﹤0.01% |
1,533,438
+72,261
| +5% | +$655K |
|
1964
Xenon Pharmaceuticals
XENE
$5.71B
| $15.1M | ﹤0.01% |
249,473
+60,393
| +32% | +$3.35M |
|
1965
Azenta
AZTA
$1.32B
| $15M | ﹤0.01% |
588,974
+61,363
| +12% | +$1.38M |
|
1966
Taysha Gene Therapies
TSHA
$1.74B
| $15M | ﹤0.01% |
2,200,695
+392,096
| +22% | +$2.32M |
|
1967
Viridian Therapeutics
VRDN
$2.58B
| $15M | ﹤0.01% |
815,027
+87,090
| +12% | +$1.4M |
|
1968
Butterfly Network
BFLY
$1.99B
| $15M | ﹤0.01% |
1,777,614
+101,022
| +6% | +$523K |
|
1969
Bit Digital
BTBT
$599M
| $15M | ﹤0.01% |
8,314,658
+190,537
| +2% | +$335K |
|
1970
Smith & Wesson
SWBI
$601M
| $14.9M | ﹤0.01% |
993,640
-214,154
| -18% | -$3.22M |
|
1971
Monte Rosa Therapeutics
GLUE
$1.22B
| $14.9M | ﹤0.01% |
616,310
+69,621
| +13% | +$1.32M |
|
|
MFA
1972
MFA Financial
MFA
$885M
| $14.9M | ﹤0.01% |
1,537,978
-28,138
| -2% | -$273K |
|
1973
IDT Corp
IDT
$1.69B
| $14.8M | ﹤0.01% |
255,279
-30,479
| -11% | -$1.61M |
|
1974
Heartland Express
HTLD
$946M
| $14.8M | ﹤0.01% |
973,500
-116,050
| -11% | -$1.57M |
|
|
OGC
1975
OceanaGold Corp
OGC
$6.92B
| $14.8M | ﹤0.01% |
+589,665
| New | +$17.6M |
|
Similar funds
Charles Schwab's Q2 2026 Portfolio in Review
As of Q2 2026, Charles Schwab held 3,591 positions worth $751B, up 15% from $654B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Charles Schwab's Q2 2026 filing shows 136 new, 2,145 increased, 1,132 reduced and 153 closed positions. Its largest new stake was Honeywell Aerospace: 2,031,187 shares worth $449M. The largest sale was Qualcomm, an estimated $1.6B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2026 buy was Honeywell Aerospace: 2,031,187 shares worth $449M.
- Charles Schwab added most to Schwab US Large-Cap Growth ETF in Q2 2026, an estimated $2.6B increase.
- Charles Schwab's biggest Q2 2026 reduction was Qualcomm, cutting an estimated $1.6B.
- Charles Schwab fully exited Coterra Energy in Q2 2026, selling an estimated $789M.
- Charles Schwab's ten largest holdings make up 22% of its $751B portfolio in Q2 2026.
- Charles Schwab opened 136 new positions and closed 153 in Q2 2026.
- Charles Schwab's portfolio value rose 15% quarter-over-quarter to $751B.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.